Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete …
S Suciu, F Mandelli, T de Witte, R Zittoun, E Gallo… - Blood, 2003 - ashpublications.org
Abstract In the European Organization for Research and Treatment of Cancer Leukemia
Group and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute …
Group and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute …
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete …
S Suciu, F Mandelli, T de Witte, R Zittoun, E Gallo… - Blood, 2003 - dial.uclouvain.be
In the European Organization for Research and Treatment of Cancer Leukemia Group and
Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute myeloid …
Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute myeloid …
[PDF][PDF] Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first …
S Suciu, F Mandelli, T de Witte, R Zittoun, E Gallo… - BLOOD, 2003 - researchgate.net
Current standard treatment strategy for patients with acute myelogenous leukemia (AML)
younger than 60 years consists of 1 or 2 induction courses with cytosine arabinoside and an …
younger than 60 years consists of 1 or 2 induction courses with cytosine arabinoside and an …
[引用][C] Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first …
S Suciu, F Mandelli, TJM de Witte, R Zittoun, E Gallo… - 2003 - repository.ubn.ru.nl
In the European Organization for Research and Treatment of Cancer Leukemia Group and
Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute myeloid …
Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute myeloid …
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete …
S Suciu, F Mandelli, T de Witte, R Zittoun, E Gallo… - …, 2003 - pubmed.ncbi.nlm.nih.gov
In the European Organization for Research and Treatment of Cancer Leukemia Group and
Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute myeloid …
Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute myeloid …
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete …
S Suciu, F Mandelli, T de Witte, R Zittoun, E Gallo… - BLOOD, 2003 - art.torvergata.it
Abstract In the European Organization for Research and Treatment of Cancer Leukemia
Group and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute …
Group and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute …
[HTML][HTML] Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first …
S Suciu, F Mandelli, T de Witte, R Zittoun, E Gallo… - Blood, 2003 - Elsevier
Abstract In the European Organization for Research and Treatment of Cancer Leukemia
Group and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute …
Group and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute …
[PDF][PDF] Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first …
S Suciu, F Mandelli, T de Witte, R Zittoun, E Gallo… - BLOOD, 2003 - Citeseer
Current standard treatment strategy for patients with acute myelogenous leukemia (AML)
younger than 60 years consists of 1 or 2 induction courses with cytosine arabinoside and an …
younger than 60 years consists of 1 or 2 induction courses with cytosine arabinoside and an …
[PDF][PDF] Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first …
S Suciu, F Mandelli, T de Witte, R Zittoun, E Gallo… - BLOOD, 2003 - academia.edu
Current standard treatment strategy for patients with acute myelogenous leukemia (AML)
younger than 60 years consists of 1 or 2 induction courses with cytosine arabinoside and an …
younger than 60 years consists of 1 or 2 induction courses with cytosine arabinoside and an …
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete …
S Suciu, F Mandelli, T de Witte, R Zittoun, E Gallo… - Blood, 2003 - europepmc.org
In the European Organization for Research and Treatment of Cancer Leukemia Group and
Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute myeloid …
Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC-LG/GIMEMA) acute myeloid …